Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease

Hepatology

Volumn 36, Issue 1, 2002, Pages 219-226

  Papatheodoridis, George V ^a   Dimou, Evangelini ^a   Laras, Andreas ^a   Papadimitropoulos, Vassilios ^a   Hadziyannis, Stephanos J ^a  

^a HENRY DUNANT HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; LIVER DISEASE; LIVER HISTOLOGY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REMISSION; SEQUENCE ANALYSIS; TREATMENT OUTCOME; VIRUS MUTANT;

EID: 0036288645     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.33894     Document Type: Article

References (24)

1. Management of hepatitis B: 2000-Summary of a workshop
2. Diagnosis and management of precore mutant chronic hepatitis B
3. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B
4. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine
5. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy
6. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
7. Long-term therapy of chronic hepatitis B with lamivudine
8. Efficacy of long-term lamivudine monotherapy in patients with HBeAg negative chronic hepatitis B
9. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
10. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
11. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine
12. Differential diagnosis of acute viral hepatitis using rapid, fully automated immunoassays
13. Evaluation of a new assay for HBV DNA quantitation in patients with chronic hepatitis B
14. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of hepatitis B virus, four of which represent two new genotypes
15. Histological grading and staging of chronic hepatitis
16. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B
17. Quantitative hepatitis B virus DNA testing for the early prediction of the maintenance of response during lamivudine therapy in patients with chronic hepatitis B
18. Chronic hepatitis B
19. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy
20. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy
21. Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B
22. Is lamivudine effective on precore/core promoter mutants of hepatitis B virus?
23. Hepatitis B e antigen-negative chronic hepatitis B
24. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy